1-4 of 4
Stephen Opat, FRACP, FRCPA, MBBS
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Analyzing Efficacy Outcomes from the Phase 2 Study of Single-Agent Tazemetostat As Third-Line Therapy in Patients with Relapsed or Refractory Follicular Lymphoma to Identify Predictors of Response

Gilles Salles, MD PhD, Hervé Tilly, MD, Aristeidis Chaidos, MD PhD, Pam McKay, MD, Tycel J. Phillips, MD, Sarit E Assouline, MD MSc, Connie Lee Batlevi, MDPhD, Philip Campbell, MBBS, Vincent Ribrag, MD, Gandhi Laurent Damaj, MD PhD, Michael Dickinson, DMed Sci, Wojciech Jurczak, MD PhD, Maciej Kaźmierczak, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, John A. Radford, MD FMedSci, Anna Schmitt, MD, Jennifer Whalen, DHS, Anthony Hamlett, PhD, Beth Kamp, PharmD, Deyaa Adib, MD, Franck Morschhauser, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 47–49.
https://doi.org/10.1182/blood-2020-137245
Published: 2020
Journal Articles

Ibrutinib (Ibr) Plus Venetoclax (Ven) for First-Line Treatment of Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL): 1-Year Disease-Free Survival (DFS) Results From the MRD Cohort of the Phase 2 CAPTIVATE Study

William G. Wierda, MD PhD, Constantine S. Tam, MD, John N. Allan, MD, Tanya Siddiqi, MD, Thomas J. Kipps, MD PhD, Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Xavier C. Badoux, MBBS, FRACP, FRCPA, Bryone J. Kuss, MBBS, PhD FRACP, FRCPA, Sharon Jackson, MD, Carol Moreno, MD PhD, Ryan Jacobs, MD, John M. Pagel, MD PhD, Ian W. Flinn, MD PhD, Cathy Zhou, MS, Edith Szafer-Glusman, PhD, Joi Ninomoto, PharmD, James P. Dean, MD PhD, Danelle F. James, MD MAS, Paolo Ghia, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 16–17.
https://doi.org/10.1182/blood-2020-134446
Published: 2020
Journal Articles

Efficacy and Safety of Zanubrutinib in Patients with Relapsed/Refractory Marginal Zone Lymphoma: Initial Results of the MAGNOLIA (BGB-3111-214) Trial

Stephen Opat, FRACP, FRCPA, MBBS, Alessandra Tedeschi, MD, Kim Linton, MBChB, MRCP, PhD, Pamela McKay, MBChB (Hons), FRCP, FRCPath, Bei Hu, MD, Henry Chan, MBChB, FRACP, FRCPA, Jie Jin, MD PhD, Pier Luigi Zinzani, MD, Peter Browett, BMedSci, MBChB, FRACP, FRCPA, Morton Coleman, MD, Magdalena Sobieraj-Teague, MBBS, FRACP, FRCPA, M.Sc, Xiaoyan Ke, MD PhD, Mingyuan Sun, MD, Robert Marcus, MA, FRCP, FRCPath, Craig A. Portell, MD, Keshu Zhou, MD PhD, Catherine Thieblemont, MD PhD, Melannie Co, MD, Weige Wang, MD, Chris Tankersley, BS, Wenxiao Zhou, M.Sc, Massimo Cappellini, BS, Jane Huang, MD, Judith Trotman, MBChB, FRACP, FRCPA
Journal: Blood
Blood (2020) 136 (Supplement 1): 28–30.
https://doi.org/10.1182/blood-2020-134611
Published: 2020
Journal Articles

Risk Profiling of Relapsed/Refractory Diffuse Large B-Cell Lymphoma Patients By Measuring Circulating Tumor DNA

Alex F. Herrera, MD, Samuel Tracy, Brandon Croft, Stephen Opat, FRACP, FRCPA, MBBS, Jill Ray, Lisa Musick, Joseph N. Paulson, Laurie H. Sehn, MDMPH, Yanwen Jiang
Journal: Blood
Blood (2020) 136 (Supplement 1): 23–25.
https://doi.org/10.1182/blood-2020-136645
Published: 2020